News about Drug Discovery & Development

Catalyst Pharmaceuticals Announces Launch of FIRDAPSE in Japan by DyDo

FIRDAPSE (amifampridine) is the only US FDA approved, evidence-based therapy for the treatment of LEMS in adults and pediatric patients six years of age and older.

Drug Discovery & Development | 22/01/2025 | By Aishwarya

Absci and Owkin Partner to Propel Generative AI in Drug Discovery

Absci Corporation and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.

Drug Discovery & Development | 21/01/2025 | By Manvi

Iconovo and Lonza to Develop Formulation of Intranasal Biologic

This project, with a reformulated substance for obesity, is the first in Iconovo’s strategic initiative to reformulate known pharmaceuticals and replace injections and oral treatments with inhalation.

Drug Discovery & Development | 14/01/2025 | By Aishwarya

Absci Partners with AMD to Propel Future of AI Drug Discovery

AMD will also make a USD 20 million investment in Absci, structured as a private investment in public equity (PIPE), underscoring the growing demand for innovative AI applications in drug discovery.

Drug Discovery & Development | 10/01/2025 | By Aishwarya

Merck KGaA Adopts Quris-AI's Bio-AI Platform for its Drug Development Pipeline

Quris-AI’s drug safety prediction platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug- induced toxicities better.

Drug Discovery & Development | 09/01/2025 | By Aishwarya

Acellera Rolls Out AceForce 1.0 to Advance Drug Discovery

AceForce 1.0 is a groundbreaking tool in computational chemistry and drug discovery, offering quantum-level accuracy by leveraging a proprietary training set of millions of quantum mechanical (QM) calculations.

Drug Discovery & Development | 08/01/2025 | By Aishwarya

WuXi Biologics Signs Deal with Candid Therapeutics to Boost Trispecific T-cell Engager

Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody platform WuXiBody.

Drug Discovery & Development | 07/01/2025 | By Aishwarya

CSIR Develops Indigenous Tech to Manufacture Paracetamol in India

Karnataka-based Satya Deeptha Pharmaceuticals Ltd will utilize this breakthrough to produce affordable paracetamol domestically.

Drug Discovery & Development | 06/01/2025 | By Aishwarya

Chime Biologics and Mabgeek Complete PPQ for MG-K10

Chime Biologics and Mabgeek's strategic collaboration, first unveiled in 2022, focuses on commercial manufacturing of cGMP 2000L drug substance, late-stage chemistry, manufacturing, and controls (CMC) development and biologics license application (BLA) to accelerate Best-in-Class biologics MG-K10's commercialization.

Drug Discovery & Development | 04/01/2025 | By Aishwarya

ANI Pharmaceuticals Introduces Prucalopride Tablets after FDA Approval

ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity.

Drug Discovery & Development | 03/01/2025 | By Aishwarya